Please login to the form below

Not currently logged in
Email:
Password:

immuno-oncology

This page shows the latest immuno-oncology news and features for those working in and with pharma, biotech and healthcare.

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC

reported results, as well as with treatment-naïve populations as previously reported at last year’s ASCO and ESMO meetings,” said Yong (Ben) Ben, chief medical officer, immuno-oncology at BeiGene.

Latest news

More from news
Approximately 80 fully matching, plus 318 partially matching documents found.

Latest Intelligence

  • BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches

    One technology that has the potential to advance the field of immuno-oncology is Amgen’s versatile Bispecific T cell Engager or BiTE platform. ... The therapeutic potential that immuno-oncology hopes to deliver is always expanding, fueled by the vision

  • Putting commercial intelligence at the heart of strategy Putting commercial intelligence at the heart of strategy

    Competitive insights. We can illustrate the need for competitive ‘insights’ with a discussion of two major players in the immuno-oncology space.

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    The merger was completed shortly after BMS reported the first decline in quarterly sales of its immuno-oncology blockbuster Opdivo (nivolumab) since its launch five years ago, and 2020 is viewed

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    Immunotherapies. The challenge now is to use predictive biomarkers for non-targeted therapies, particularly in areas like immuno-oncology where determining likely response to treatment is crucial. ... Finding and using such biomarkers is complicated,

  • 25 Women Leaders in UK Healthcare 25 Women Leaders in UK Healthcare

    its role in developing immuno-oncology blockbuster Keytruda. ... Commenting on her colleague, Susan Galbraith, head of oncology at AstraZeneca’s IMED Biotech unit (and herself one of our listed leaders last year), said: “Ruth has helped transform

More from intelligence
Approximately 3 fully matching, plus 57 partially matching documents found.

Latest appointments

  • Evoke KYNE promotes Dante DelVecchio to senior VP Evoke KYNE promotes Dante DelVecchio to senior VP

    In his new role, he will become a member of the firm’s senior management team, and will continue to oversee key client engagements in infectious diseases, vaccines and immuno-oncology.

  • New hires at Crescendo, Healx and Galecto New hires at Crescendo, Healx and Galecto

    The latest movers in pharma. Crescendo. Crescendo Biologics has appointed Kenji Hashimoto as its new chief medical officer, who joins Crescendo with over 15 years of experience in oncology and ... Kenji has considerable immuno-oncology expertise and an

  • F-star hires ex-BMS immuno-oncology leader

    Dr Kayitalire has over 20 years’ experience in oncology and immuno-oncology (IO) including spells at Celgene and Eli Lilly as well as BMS. ... Another key role for him will be in leading the clinical strategy and operations for F-star’s pipeline of

  • New hires at Ferring, Flexion and Immunocore New hires at Ferring, Flexion and Immunocore

    leadership team.”. Opdyke, who has more than 20 years’ experience, joins Ferring from Pfizer, where she most recently served as vice president, immuno-oncology lead. ... Over his career, Berman has worked on immuno-oncology programmes at all stages

  • Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO

    A champion for science and diversity, Bahija is a highly seasoned pharmaceutical executive with considerable experience in biologics R&D and immuno-oncology.

More from appointments
Approximately 0 fully matching, plus 36 partially matching documents found.

Latest from PMHub

  • Havas Lynx Group Havas Lynx Group

    18 SWITCHED ONcology: The Big Communication. ... Matching unprecedented clinical advances in immuno-oncology with transformative communication.

  • Lucid Group adds more magic to the mix with four new hires

    Betty has worked on a wide variety of medical education initiatives in various therapeutic areas including immuno-oncology, infectious diseases, transplantation and multiple sclerosis. ... Megan has experience in cardiology, vaccines, dermatology and

  • Lucid Group strengthens its scientific leadership and client service team with two new hires

    editorial. With expertise in COPD, oncology and behaviour-change patient support programmes Eva is a magical addition to the team. ... Lizzie has previously worked in Global, European, and UK roles with experience in several therapy areas including immuno

  • Random42 attending Biotech Showcase in San Francisco

    Alzheimer’s Disease. Cell and Gene Therapy. Immuno-Oncology. NASH (Nonalcoholic steatohepatitis). Rare and Orphan Diseases.

  • SWITCHED ONcology

    We are stronger together. We are Switched ON. Switched ONcology is the latest thought leadership campaign from the award-winning Havas lynx portfolio. ... The campaign provides our partners with deeper insight, smarter ideas and more meaningful

More from PMHub
Approximately 18 fully matching, plus 10 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics